Background and Purpose:
Hydroxychloroquine and chloroquine, alone or in combination with
azithromycin, have been proposed as therapies for COVID-19. However,
there is currently scant and inconsistent data regarding their
proarrhythmic potential in these patients. Moreover, their risk profile
in the setting of altered physiological states encountered in patients
with COVID-19 (i.e. febrile state, electrolyte imbalances, and/or
acidosis) is unknown.